The Effect of Exercise on the Brain in Type 2 Diabetes
NCT06734546, Not applicable, Recruiting, Hasselt University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effect of Exercise on the Brain in Type 2 Diabetes | ClinicalTrials.gov |
| NCT number | NCT06734546 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 75 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Hasselt University | ClinicalTrials.gov |
| Conditions | Type 2 Diabetes | ClinicalTrials.gov |
| Interventions | Exercise intervention | ClinicalTrials.gov |
| First posted | 2024-12-16 | ClinicalTrials.gov |
| Last updated | 2026-03-31 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Neurometabolite levels | From enrollment to the end of treatment at 6 months | Levels of N-acetylaspartate, choline, myo-inositol, creatine, glutathion, and glutamate, measured in institutional units (i.u.) by means of magnetic resonance spectroscopy (MRS). | ClinicalTrials.gov |
| Primary | Changes in arterial spin labelling measured by means of magnetic resonance imaging (MRI) | From enrollment to the end of treatment at 6 months | Changes in cerebral perfusion expressed in mL/100g/min, and blood flow through the blood-brain-barrier expressed in milliseconds | ClinicalTrials.gov |
| Secondary | Levels of neurodegenerative blood biomarkers | From enrollment to the end of treatment at 6 months | Tau (pg/mL), amyloid beta (pg/mL), S100B (ng/mL), neurofilament light (pg/mL) etc. | ClinicalTrials.gov |
| Secondary | Blood lipid profile | From enrollment to the end of treatment at 6 months | This outcome measure includes assessments of the lipid profile, reported in milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L): High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), Triglycerides, Free Fatty Acids, Total Cholesterol | ClinicalTrials.gov |
| Secondary | Brain volume | From enrollment to the end of treatment at 6 months | Total and regional (LHIPP, mPFC, PCC) brain volumes | ClinicalTrials.gov |
| Secondary | Diffusion-weighted magnetic resonance imaging | From enrollment to the end of treatment at 6 months | DWI will be used to measure differences in Brownian motion of water molecules within the brain | ClinicalTrials.gov |
| Secondary | Fasted blood glucose | From enrollment to the end of treatment at 6 months | Fasting Glucose: Reported in milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L). | ClinicalTrials.gov |
| Secondary | Kidney function (eGFR) | From enrollment to the end of treatment at 6 months | Estimated Glomerular Filtration Rate (eGFR): Reported in milliliters per minute per 1.73 m² (mL/min/1.73 m²). | ClinicalTrials.gov |
| Secondary | Cognitive function: MoCA | From enrollment to the end of treatment at 6 months | Cognitive function as assessed by the Montreal Cognitive Assessment (MoCA), scored on a scale of 0-30. | ClinicalTrials.gov |
| Secondary | Cognitive function: Face recognition test | From enrollment to the end of treatment at 6 months | Cognitive function as assessed by the Face Recognition Test, reported as the number of correct identifications. | ClinicalTrials.gov |
| Secondary | Cognitive function: Object location test | From enrollment to the end of treatment at 6 months | Cognitive function as assessed by the Object Location Test, reported as the number of correct placements. | ClinicalTrials.gov |
| Secondary | Cognitive function: Trail making test | From enrollment to the end of treatment at 6 months | Cognitive function as assessed by the Trail Making Test, reported as time to completion (seconds) for Parts A and B. | ClinicalTrials.gov |
| Secondary | Cognitive function: Stroop colour and word test | From enrollment to the end of treatment at 6 months | Cognitive function as assessed by the Stroop Color and Word Test, reported as time to completion (seconds) or number of errors. | ClinicalTrials.gov |
| Secondary | Cognitive function: Rey auditory verbal learning test | From enrollment to the end of treatment at 6 months | Cognitive function as assessed by the Rey Auditory Verbal Learning Test, reported as the number of words recalled. | ClinicalTrials.gov |
| Secondary | Subjective cognitive function | From enrollment to the end of treatment at 6 months | Cognitive function as assessed by the Cognitive Failure Questionnaire, scored on a scale of 0-100. | ClinicalTrials.gov |
| Secondary | Peak load during CPET | From enrollment to the end of treatment at 6 months | The maximum load achieved during cardiopulmonary exercise testing (CPET) on a bicycle, measured in watts. | ClinicalTrials.gov |
| Secondary | VO2peak during CPET | From enrollment to the end of treatment at 6 months | The peak oxygen consumption measured during CPET, indicating the maximal capacity for oxygen utilization during exercise. Unit of Measure: Milliliters per kilogram per minute (mL/kg/min). | ClinicalTrials.gov |
| Secondary | Fasted blood HbA1c | From enrollment to the end of treatment at 6 months | Hemoglobin A1c (HbA1c): Reported as a percentage (%). | ClinicalTrials.gov |
| Secondary | Fasting insulin | From enrollment to the end of treatment at 6 months | Fasting Insulin: Reported in micro-international units per milliliter (μIU/mL) or picomoles per liter (pmol/L). | ClinicalTrials.gov |
| Secondary | Kidney function (creatinine) | From enrollment to the end of treatment at 6 months | Creatinine: Reported in milligrams per deciliter (mg/dL) or micromoles per liter (μmol/L). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)